Literature DB >> 23585562

Prostate-derived sterile 20-like kinases (PSKs/TAOKs) phosphorylate tau protein and are activated in tangle-bearing neurons in Alzheimer disease.

Ignatius A Tavares1, Dona Touma, Steven Lynham, Claire Troakes, Megan Schober, Mirsada Causevic, Ritu Garg, Wendy Noble, Richard Killick, Istvan Bodi, Diane P Hanger, Jonathan D H Morris.   

Abstract

In Alzheimer disease (AD), the microtubule-associated protein tau is highly phosphorylated and aggregates into characteristic neurofibrillary tangles. Prostate-derived sterile 20-like kinases (PSKs/TAOKs) 1 and 2, members of the sterile 20 family of kinases, have been shown to regulate microtubule stability and organization. Here we show that tau is a good substrate for PSK1 and PSK2 phosphorylation with mass spectrometric analysis of phosphorylated tau revealing more than 40 tau residues as targets of these kinases. Notably, phosphorylated residues include motifs located within the microtubule-binding repeat domain on tau (Ser-262, Ser-324, and Ser-356), sites that are known to regulate tau-microtubule interactions. PSK catalytic activity is enhanced in the entorhinal cortex and hippocampus, areas of the brain that are most susceptible to Alzheimer pathology, in comparison with the cerebellum, which is relatively spared. Activated PSK is associated with neurofibrillary tangles, dystrophic neurites surrounding neuritic plaques, neuropil threads, and granulovacuolar degeneration bodies in AD brain. By contrast, activated PSKs and phosphorylated tau are rarely detectible in immunostained control human brain. Our results demonstrate that tau is a substrate for PSK and suggest that this family of kinases could contribute to the development of AD pathology and dementia.

Entities:  

Keywords:  Alzheimer Disease; Kinase; MAP Kinases (MAPKs); MAPs; Neurodegenerative Diseases; Neurofibrillary Tangles; PSK Kinases; Phosphorylation; Signal Transduction; Tau

Mesh:

Substances:

Year:  2013        PMID: 23585562      PMCID: PMC3663559          DOI: 10.1074/jbc.M112.448183

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  62 in total

Review 1.  Neurodegenerative tauopathies.

Authors:  V M Lee; M Goedert; J Q Trojanowski
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

Review 2.  MAPs, MARKs and microtubule dynamics.

Authors:  G Drewes; A Ebneth; E M Mandelkow
Journal:  Trends Biochem Sci       Date:  1998-08       Impact factor: 13.807

3.  Tau is a candidate gene for chromosome 17 frontotemporal dementia.

Authors:  P Poorkaj; T D Bird; E Wijsman; E Nemens; R M Garruto; L Anderson; A Andreadis; W C Wiederholt; M Raskind; G D Schellenberg
Journal:  Ann Neurol       Date:  1998-06       Impact factor: 10.422

4.  Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding.

Authors:  Jae-Hyeon Cho; Gail V W Johnson
Journal:  J Biol Chem       Date:  2002-10-29       Impact factor: 5.157

5.  Signaling from MARK to tau: regulation, cytoskeletal crosstalk, and pathological phosphorylation.

Authors:  T Timm; D Matenia; X-Y Li; B Griesshaber; E-M Mandelkow
Journal:  Neurodegener Dis       Date:  2006       Impact factor: 2.977

6.  Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments.

Authors:  A Schneider; J Biernat; M von Bergen; E Mandelkow; E M Mandelkow
Journal:  Biochemistry       Date:  1999-03-23       Impact factor: 3.162

7.  Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies.

Authors:  I Ferrer; R Blanco; M Carmona; B Puig
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

Review 8.  Biochemistry and cell biology of tau protein in neurofibrillary degeneration.

Authors:  Eva-Maria Mandelkow; Eckhard Mandelkow
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

Review 9.  Tau-based treatment strategies in neurodegenerative diseases.

Authors:  Anja Schneider; Eckhard Mandelkow
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

Review 10.  The mammalian family of sterile 20p-like protein kinases.

Authors:  Eric Delpire
Journal:  Pflugers Arch       Date:  2009-04-28       Impact factor: 3.657

View more
  21 in total

1.  Neuronal calcineurin transcriptional targets parallel changes observed in Alzheimer disease brain.

Authors:  Sarah C Hopp; Nathan A Bihlmeyer; John P Corradi; Charles Vanderburg; Angela M Cacace; Sudeshna Das; Timothy W Clark; Rebecca A Betensky; Bradley T Hyman; Eloise Hudry
Journal:  J Neurochem       Date:  2018-09-07       Impact factor: 5.372

Review 2.  Roles of tau protein in health and disease.

Authors:  Tong Guo; Wendy Noble; Diane P Hanger
Journal:  Acta Neuropathol       Date:  2017-04-06       Impact factor: 17.088

3.  TAOK2 Kinase Mediates PSD95 Stability and Dendritic Spine Maturation through Septin7 Phosphorylation.

Authors:  Smita Yadav; Juan A Oses-Prieto; Christian J Peters; Jing Zhou; Samuel J Pleasure; Alma L Burlingame; Lily Y Jan; Yuh-Nung Jan
Journal:  Neuron       Date:  2017-01-05       Impact factor: 17.173

4.  Amyloid β-Exposed Human Astrocytes Overproduce Phospho-Tau and Overrelease It within Exosomes, Effects Suppressed by Calcilytic NPS 2143-Further Implications for Alzheimer's Therapy.

Authors:  Anna Chiarini; Ubaldo Armato; Emanuela Gardenal; Li Gui; Ilaria Dal Prà
Journal:  Front Neurosci       Date:  2017-04-20       Impact factor: 4.677

5.  Chromosome 19q13 disruption alters expressions of CYP2A7, MIA and MIA-RAB4B lncRNA and contributes to FAP-like phenotype in APC mutation-negative familial colorectal cancer patients.

Authors:  Lai Fun Thean; Yu Hui Wong; Michelle Lo; Carol Loi; Min Hoe Chew; Choong Leong Tang; Peh Yean Cheah
Journal:  PLoS One       Date:  2017-03-17       Impact factor: 3.240

6.  A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies.

Authors:  Caterina Giacomini; Chuay-Yeng Koo; Natalia Yankova; Ignatius A Tavares; Selina Wray; Wendy Noble; Diane P Hanger; Jonathan D H Morris
Journal:  Acta Neuropathol Commun       Date:  2018-05-07       Impact factor: 7.801

Review 7.  Alzheimer's Disease Animal Models: Elucidation of Biomarkers and Therapeutic Approaches for Cognitive Impairment.

Authors:  Tsuyoshi Nakai; Kiyofumi Yamada; Hiroyuki Mizoguchi
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

8.  A machine learning approach to brain epigenetic analysis reveals kinases associated with Alzheimer's disease.

Authors:  Yanting Huang; Xiaobo Sun; Huige Jiang; Shaojun Yu; Chloe Robins; Matthew J Armstrong; Ronghua Li; Zhen Mei; Xiaochuan Shi; Ekaterina Sergeevna Gerasimov; Philip L De Jager; David A Bennett; Aliza P Wingo; Peng Jin; Thomas S Wingo; Zhaohui S Qin
Journal:  Nat Commun       Date:  2021-07-22       Impact factor: 17.694

9.  The importance of tau phosphorylation for neurodegenerative diseases.

Authors:  Wendy Noble; Diane P Hanger; Christopher C J Miller; Simon Lovestone
Journal:  Front Neurol       Date:  2013-07-01       Impact factor: 4.003

10.  MicroRNA-146a suppresses ROCK1 allowing hyperphosphorylation of tau in Alzheimer's disease.

Authors:  Gang Wang; Yue Huang; Li-Ling Wang; Yong-Fang Zhang; Jing Xu; Yi Zhou; Guinevere F Lourenco; Bei Zhang; Ying Wang; Ru-Jing Ren; Glenda M Halliday; Sheng-Di Chen
Journal:  Sci Rep       Date:  2016-05-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.